NeuroMetrix Inc stock (US64132K1025): Nasdaq micro-cap trades quietly after last reported quarterly results

NeuroMetrix Inc shares continue to trade at low absolute levels on Nasdaq, with the last reported quarterly figures from November 2024 still providing the main fundamental anchor for the United States-based neurotechnology micro-cap.

NeuroMetrix Inc shares remain a thinly traded micro-cap on the Nasdaq Capital Market in the United States, with investors still looking back to the company’s last reported quarterly figures from November 2024 for fundamental orientation around the stock.

According to Nasdaq, NeuroMetrix Inc last changed hands on the Nasdaq Capital Market under the ticker NURO, reflecting its status as a small-cap medical device name focused on neurotechnology applications in the United States healthcare market, and the company continues to be listed on this U.S. exchange as of early June 2026, without any completed take-private transaction or confirmed delisting reported by regulators or the company itself.

In its most recent available quarterly report, NeuroMetrix Inc released financial results for the quarter ended 09/30/2024 in a press release dated 11/05/2024, providing one of the latest detailed snapshots of its operating performance and balance sheet for investors monitoring the company’s progress.

In that 11/05/2024 earnings announcement, the company reported quarterly revenue and earnings metrics for the three months ended 09/30/2024, along with commentary on its product portfolio, development initiatives and the challenges of operating as a commercial-stage neurotechnology developer focused on medical devices for pain management and related indications.

The 11/05/2024 communication also offered insight into cash resources and operating expenses as of 09/30/2024, which remain key considerations for market participants given the company’s limited scale, negative earnings and reliance on a narrow set of neurotechnology products and associated services.

Per company and exchange data compiled by MarketBeat, NeuroMetrix Inc is categorized within the medical sector, specifically the medical equipment and surgical and medical instruments space, underlining that its primary business activity is the design and commercialization of devices that stimulate and analyze nerve function for diagnostic and therapeutic use.

MarketBeat data as of 06/02/2026 describes NeuroMetrix Inc as a commercial-stage neurotechnology company with approximately 20 employees, headquartered in Woburn, Massachusetts, indicating a lean organizational setup that is typical for highly specialized medical device developers operating at micro-cap scale.

The same MarketBeat overview referencing 06/02/2026 notes that for the trailing twelve months NeuroMetrix Inc generated a net loss of about USD 6.53 million, translating into negative earnings per share of roughly USD 4.59, reinforcing the view that the company is still in a loss-making phase as it invests in product development and commercialization rather than delivering consistent bottom-line profitability.

With a trailing twelve-month price-to-earnings ratio that cannot be meaningfully calculated due to negative EPS, valuation exercises on NeuroMetrix Inc at the current stage tend to focus instead on metrics such as enterprise value to revenue, cash runway and scenario-based estimates for potential adoption of its therapeutic and diagnostic devices.

Because NeuroMetrix Inc trades in the United States on Nasdaq under the ticker NURO, most liquidity is concentrated in U.S. dollars on the home exchange, and secondary trading activity on German platforms such as Tradegate or Frankfurt, where available, tends to be comparatively modest and often reflects the spreads and volumes observed in the U.S. market.

The stock’s micro-cap nature means that day-to-day price changes can be driven as much by shifts in investor risk appetite and small order flows as by company-specific news, and without a fresh earnings release since the 11/05/2024 quarterly update, many market participants continue to reference those historical numbers and more recent trailing-loss data to frame expectations.

As is typical for small healthcare technology and medical device firms, NeuroMetrix Inc’s share price on Nasdaq can also react sharply to any regulatory decisions, reimbursement developments, or clinical data updates that directly influence the commercial potential of its neurotechnology offerings, even though no such major event has been reported by the company or regulators in the first half of 2026 based on publicly accessible filings.

The combination of negative trailing earnings, small absolute market capitalization and concentrated product exposure implies that the stock carries a risk profile distinct from that of larger diversified medical technology companies, and investors often scrutinize cash burn and funding options closely when interpreting the implications of the 09/30/2024 financial data.

Given the absence of newer reported financials since the 11/05/2024 quarterly release, many observers continue to interpret the trailing twelve-month loss of approximately USD 6.53 million and negative EPS of roughly USD 4.59, as cited by MarketBeat as of 06/02/2026, as important indicators of the company’s need to grow revenue or manage costs to extend its financial runway.

In this context, any forthcoming update to quarterly or full-year results filed with the U.S. Securities and Exchange Commission or released through the company’s investor relations site will likely serve as the next major fundamental catalyst for NeuroMetrix Inc, particularly if it provides clarity on revenue momentum, gross margins, operating expenses and capital needs beyond what was available in the 09/30/2024 data set.

As of: 06/05/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: NeuroMetrix Inc
• Sector/industry: Medical equipment, neurotechnology-focused devices
• Headquarters/country: Woburn, United States
• Core markets: United States pain management and neurology practices
• Key revenue drivers: Sales of nerve stimulation and diagnostic devices and related services
• Home exchange/listing venue: Nasdaq Capital Market (NURO)
• Trading currency: USD

NeuroMetrix Inc: core business model

NeuroMetrix Inc concentrates on designing, building and selling neurotechnology-based medical devices that clinicians use to diagnose and treat nerve-related conditions, with revenues mainly derived from device sales, consumables and associated clinical services.

Valuation metrics and multiples for NeuroMetrix Inc

Because NeuroMetrix Inc currently posts negative earnings on a trailing twelve-month basis, traditional valuation ratios such as the price-to-earnings multiple are not available, so investors often examine alternative indicators when assessing the stock’s valuation profile.

MarketBeat data updated as of 06/02/2026 indicates that NeuroMetrix Inc recorded trailing twelve-month earnings per share of approximately USD -4.59 and a net loss of around USD 6.53 million, which together signal that the company is still in an investment and development phase rather than a steady profit-generating stage, and this loss profile feeds into assessments of enterprise value relative to past and potential future revenue.

Given the absence of a current dividend program and the fact that the company has not declared regular cash distributions to shareholders in the recent reporting periods around 11/05/2024, dividend yield is not a relevant measure for NeuroMetrix Inc, and many valuation frameworks instead prioritize liquidity, cash runway and the potential scalability of its neurotechnology platform in the U.S. healthcare system.

With only limited analyst coverage and sparse comparable peers trading at similar scales on Nasdaq, implied valuation ranges for NeuroMetrix Inc can vary materially depending on assumptions about future product adoption, reimbursement dynamics and the likelihood of strategic partnerships or licensing arrangements that could leverage its intellectual property in nerve stimulation and diagnostic technologies.

Conclusion

NeuroMetrix Inc remains an actively listed Nasdaq micro-cap with its last fully detailed quarterly update dated 11/05/2024, and trailing data compiled as of 06/02/2026 still point to negative earnings and a net loss on a twelve-month basis.

From a valuation perspective, the absence of positive EPS and dividends shifts attention to cash resources, revenue traction and the scalability of the company’s neurotechnology platform, while thin trading volumes and concentrated product exposure add a layer of volatility typical for specialized medical device names.

Upcoming earnings releases or material regulatory developments will therefore be closely watched by market participants as they reassess how the 09/30/2024 financial profile and the trailing loss of around USD 6.53 million relate to any new information on growth prospects, funding and strategic options for NeuroMetrix Inc.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.